Economy, business, innovation

Markets

Spruce Power Holding Corporation (SPRU) Reports Q4 Earnings

SPRU|EPS -$0.38|Rev $24.0M|Net Loss $6.8M Spruce Power Holding Corporation (SPRU) reported Q4 2025 reported earnings of -$0.38 per share. Revenue totaled $24.0M for the quarter. Revenue of $24.0M was up 19.0% year-over-year. Spruce Power Holding Corporation is a Solar company. Operating EBITDA was 16,995,000 dollars for the quarter. The company operated 84,000 home solar assets […]

Spruce Power Holding Corporation (SPRU) Reports Q4 Earnings Read More »

iHuman Inc. (IH) Reports Q4 Earnings

IH|EPS ¥0.29|Rev ¥190.7M|Net Income ¥15.4M iHuman Inc. reported diluted earnings of ¥0.29 per share for the fourth quarter of 2025, as the Chinese education technology company navigated a challenging year-over-year comparison. The company generated ¥190.7M in revenue for the quarter, down 18.1% from the ¥232.7M recorded in Q4 2024. The New York Stock Exchange-listed company,

iHuman Inc. (IH) Reports Q4 Earnings Read More »

DiaMedica Therapeutics 2025 Financial Review

Company Overview DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. Key Financial Figures For the year ended December 31, 2025, DiaMedica reported $0 in revenue. The company’s basic and diluted net loss per share (EPS) was $(0.70). Overall net loss for the year totaled

DiaMedica Therapeutics 2025 Financial Review Read More »

Jiayin Group Inc. (JFIN) Reports Q4 Earnings

JFIN|EPS ¥0.49|Rev ¥1.09B|Net Income ¥100.6M Jiayin Group Inc. reported sharply lower fourth-quarter results as China’s online consumer finance provider grappled with deteriorating asset quality and a contracting loan book. The company posted net income of ¥100.6M for the three months ended December, translating to earnings of ¥0.49 per share, down 62.3% from ¥1.30 per share

Jiayin Group Inc. (JFIN) Reports Q4 Earnings Read More »

VerifyMe 2025 Financial Results Analysis

Company Overview VerifyMe, Inc. provides brand protection and precision logistics solutions for time- and temperature-sensitive products. Key Financial Figures The company reported a 2025 annual revenue of $16.4 million. Fourth-quarter revenue was $2.4 million. Earnings Per Share (EPS) is omitted as it is not provided in the source document. Additional Financial Insights VerifyMe ended 2025

VerifyMe 2025 Financial Results Analysis Read More »

Lantern Pharma 2025 Financial Update

Company Overview Lantern Pharma is an oncology company utilizing its AI platform, RADR, to advance precision drug development. It maintains a pipeline of targeted therapies for rare and hard-to-treat cancers. Key Financial Figures For the year ended December 31, 2025, Lantern Pharma did not report any top-line revenue. The company’s net loss per common share

Lantern Pharma 2025 Financial Update Read More »

Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings

JSPR|EPS -$0.32|Net Loss $9.1M Jasper Therapeutics, Inc. reported a significantly narrower loss for the fourth quarter of 2025, reflecting improved cost management at the clinical-stage biotechnology company. The firm posted a loss of $0.32 per share for the quarter, compared with a loss of $1.62 per share in the same period a year earlier, representing

Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings Read More »

Scroll to Top